XML 30 R12.htm IDEA: XBRL DOCUMENT
v3.22.1

Restructuring, Impairment, and Related Charges | 12 Months Ended
--- | ---
Mar. 31, 2022
Restructuring and Related Activities [Abstract] |
Restructuring, Impairment, and Related Charges | Restructuring, Impairment, and Related Charges, Net The Company recorded restructuring, impairment, and related charges, net, of $281 million, $334 million, and $268 million in 2022, 2021, and 2020, respectively. These charges are included in “Restructuring, impairment, and related charges, net” in the Consolidated Statements of Operations. In addition, for the years ended March 31, 2021 and 2020, certain charges related to restructuring initiatives were included in “Cost of sales” in the Consolidated Statements of Operations and were not material. Restructuring Initiatives During the first quarter of 2022, the Company approved an initiative to increase operational efficiencies and flexibility by transitioning to a partial remote work model for certain employees. This initiative primarily included the rationalization of the Company’s office space in North America. Where the Company ceased using office space, it exited the portion of the facility no longer used. It also retained and repurposed certain other office locations. The Company recorded charges of $124 million for the year ended March 31, 2022, primarily related to lease right-of-use and other long-lived asset impairments, lease exit costs, and accelerated depreciation and amortization. This initiative was substantially complete in 2022 after which immaterial charges will continue to be incurred through the termination date of certain leases. During the first quarter of 2021, the Company committed to an initiative within the United Kingdom (“U.K.”), which is included in the Company’s International segment, to further drive operational changes in technologies and business processes, efficiencies, and cost savings. The initiative included reducing the number of retail pharmacy stores, decommissioning obsolete technologies and processes, reorganizing and consolidating certain business operations, and related headcount reductions. Charges incurred for this initiative were not material for the year ended March 31, 2022 and were $57 million for the year ended March 31, 2021, primarily related to asset impairments and accelerated depreciation expense as well as employee severance and other employee-related costs. This initiative was substantially complete in 2022 and remaining costs the Company expects to record under this initiative are not material. During the fourth quarter of 2019, the Company committed to certain programs to continue its operating model and cost optimization efforts. The Company continues to implement centralization of certain functions and outsourcing through an expanded arrangement with a third-party vendor to achieve operational efficiency. The programs also include reorganization and consolidation of business operations, related headcount reductions, the further closures of retail pharmacy stores in Europe, and closures of other facilities. The Company recorded charges of $62 million and $72 million in 2021 and 2020, respectively, consisting primarily of employee severance, accelerated depreciation expense, and project consulting fees. This initiative was substantially complete in 2021 and remaining costs the Company recorded under this initiative were not material. As previously announced on November 30, 2018, the Company relocated its corporate headquarters, effective April 1, 2019, from San Francisco, California to Irving, Texas to improve efficiency, collaboration, and cost competitiveness. As a result, the Company recorded charges of $28 million and $44 million in 2021 and 2020, respectively, consisting primarily of employee retention expenses, severance, long-lived asset impairments, and accelerated depreciation. The relocation was substantially complete in January 2021 and remaining costs the Company recorded under this initiative, primarily relating to lease costs, were not material. On April 25, 2018, the Company announced a strategic growth initiative intended to drive long-term incremental profit growth and to increase operational efficiency. The initiative consisted of multiple growth priorities and plans to optimize the Company’s operating models and cost structures primarily through centralization, cost management, and outsourcing of certain administrative functions. As part of the growth initiative, the Company committed to implement certain actions including a reduction in workforce, facility consolidation, and store closures. This set of initiatives was substantially complete by the end of 2020 and charges in 2021 were not material. The Company recorded charges of $15 million in 2020. Fiscal 2022 Restructuring, impairment, and related charges, net for the year ended March 31, 2022 consisted of the following:
| Year Ended March 31, 2022
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 8 |  |  | $ | 1 |  |  | $ | (1) |  |  | $ | 8 |  |  | $ | (7) |  |  | $ | 9 |
Exit and other-related costs (1) | 9 |  |  | 4 |  |  | 5 |  |  | 33 |  |  | 46 |  |  | 97 |
Asset impairments and accelerated depreciation (2) | 18 |  |  | 20 |  |  | 5 |  |  | 35 |  |  | 61 |  |  | 139 |
Total | $ | 35 |  |  | $ | 25 |  |  | $ | 9 |  |  | $ | 76 |  |  | $ | 100 |  |  | $ | 245 |
(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. For the Company’s International segment, costs primarily relate to optimization programs in Canada, exit-related actions for the Company’s European Divestiture Activities, and programs for operating model and cost optimization efforts in the U.K. as described above. For Corporate, primarily represents costs related to the transition to the partial remote work model described above and various other initiatives. (2)Costs primarily relate to the transition to the partial remote work model described above. Fiscal 2021 Restructuring, impairment, and related charges, net for the year ended March 31, 2021 consisted of the following:
| Year Ended March 31, 2021
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International (1) |  | Corporate (2) |  | Total
Severance and employee-related costs, net | $ | 10 |  |  | $ | 4 |  |  | $ | (1) |  |  | $ | 22 |  |  | $ | 69 |  |  | $ | 104 |
Exit and other-related costs (3) | 11 |  |  | — |  |  | 4 |  |  | 17 |  |  | 27 |  |  | 59 |
Asset impairments and accelerated depreciation | — |  |  | — |  |  | 1 |  |  | 46 |  |  | 9 |  |  | 56 |
Total | $ | 21 |  |  | $ | 4 |  |  | $ | 4 |  |  | $ | 85 |  |  | $ | 105 |  |  | $ | 219 |
(1)Primarily represents costs associated with the operating model and cost optimization efforts described above. (2)Represents costs associated with the operating model cost optimization efforts and the relocation of the Company’s headquarters described above in addition to various other initiatives. (3)Exit and other-related costs primarily include project consulting fees. Fiscal 2020 Restructuring, impairment, and related charges, net for the year ended March 31, 2020 consisted of the following:
| Year Ended March 31, 2020
(In millions) | U.S. Pharmaceutical (1) |  | Prescription Technology Solutions |  | Medical-Surgical Solutions (2) |  | International (3) |  | Corporate (4) |  | Total
Severance and employee-related costs, net | $ | 12 |  |  | $ | (1) |  |  | $ | 4 |  |  | $ | 2 |  |  | $ | 30 |  |  | $ | 47 |
Exit and other-related costs (5) | 1 |  |  | — |  |  | 19 |  |  | 13 |  |  | 46 |  |  | 79 |
Asset impairments and accelerated depreciation | 10 |  |  | — |  |  | 1 |  |  | 6 |  |  | 13 |  |  | 30 |
Total | $ | 23 |  |  | $ | (1) |  |  | $ | 24 |  |  | $ | 21 |  |  | $ | 89 |  |  | $ | 156 |
(1)Represents costs associated with dispositions and costs related to the relocation of the Company’s corporate headquarters described above. (2)Primarily represents costs associated with the growth initiative described above. (3)Primarily represents costs associated with the operating model and cost optimization efforts described above. (4)Represents costs associated with the growth initiative, operating model cost optimization efforts, and with the relocation of the Company’s corporate headquarters described above. (5)Exit and other-related costs primarily include project consulting fees. The following table summarizes the activity related to the restructuring liabilities associated with the Company’s restructuring initiatives for the years ended March 31, 2022 and 2021:
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Balance, March 31, 2020 | $ | 29 |  |  | $ | 1 |  |  | $ | 22 |  |  | $ | 66 |  |  | $ | 39 |  |  | $ | 157 |
Restructuring, impairment, and related charges, net | 21 |  | 4 |  |  | 4 |  |  | 85 |  |  | 105 |  |  | 219
Non-cash charges | — |  |  | — |  |  | (1) |  |  | (46) |  |  | (9) |  |  | (56) |
Cash payments | (31) |  |  | (1) |  |  | (21) |  |  | (31) |  |  | (75) |  |  | (159) |
Other | — |  |  | — |  |  | (1) |  |  | (8) |  |  | (1) |  |  | (10) |
Balance, March 31, 2021 (1) | 19 |  |  | 4 |  |  | 3 |  |  | 66 |  |  | 59 |  |  | 151 |
Restructuring, impairment, and related charges, net | 35 |  |  | 25 |  |  | 9 |  |  | 76 |  |  | 100 |  |  | 245 |
Non-cash charges | (18) |  |  | (20) |  |  | (5) |  |  | (35) |  |  | (61) |  |  | (139) |
Cash payments | (18) |  |  | (6) |  |  | (6) |  |  | (28) |  |  | (29) |  |  | (87) |
Other | (7) |  |  | — |  |  | — |  |  | (23) |  |  | (10) |  |  | (40) |
Balance, March 31, 2022 (2) | $ | 11 |  |  | $ | 3 |  |  | $ | 1 |  |  | $ | 56 |  |  | $ | 59 |  |  | $ | 130 |
(1) As of March 31, 2021, the total reserve balance was $151 million, of which $99 million was recorded in “Other accrued liabilities” and $52 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheets. (2) As of March 31, 2022, the total reserve balance was $130 million, of which $58 million was recorded in “Other accrued liabilities,” $36 million was recorded in “Liabilities held for sale,” and $36 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheets. Long-Lived Asset Impairments Fiscal 2022 In 2022, the Company recognized charges totaling $36 million to impair certain long-lived assets within the International segment related to the Company’s operations in Denmark and its retail pharmacy businesses in Canada. The Company used an income approach (a DCF method) and a market approach to estimate the fair value of the long-lived assets. Fiscal 2021 In 2021, the Company recognized charges of $115 million to impair certain long-lived assets within the Company’s International segment. These charges primarily related to long-lived assets associated with the Company’s retail pharmacy businesses in Canada and Europe and were due to declines in estimated future cash flows partially driven by a revised outlook regarding the impacts of COVID-19. The Company used both an income approach and a market approach to estimate the fair value of the long-lived assets. Fiscal 2020 In 2020, the Company recognized charges of $82 million to impair certain long-lived and intangible assets for its retail pharmacy business in Europe within the Company’s International segment. These charges related primarily to intangible assets associated with pharmacy licenses within the U.K. retail business due to a decline in estimated future cash flows driven by additional U.K. government reimbursement reductions communicated in the third quarter of 2020. The Company used a combination of an income approach and a market approach to estimate the fair value of the long-lived and intangible assets. In 2020, the Company performed an interim impairment test of long-lived and intangible assets for its Rexall Health retail business, within the Company's International segment, due to the decline in the estimated future cash flows primarily driven by lower than expected growth in both prescription volume and sales of non-prescription goods. As a result, the Company recognized a charge of $30 million to impair certain long-lived and intangible assets, primarily customer relationships. The Company used an income approach for estimating the fair value of the long-lived and intangible assets.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(e)) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -URI http://asc.fasb.org/topic&trid=2175745 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration